Last reviewed · How we verify
Sertraline [Zoloft]
Sertraline selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain.
Sertraline selectively inhibits the reuptake of serotonin at the neuronal synapse, increasing serotonin availability in the brain. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.
At a glance
| Generic name | Sertraline [Zoloft] |
|---|---|
| Sponsor | Johns Hopkins University |
| Drug class | Selective serotonin reuptake inhibitor (SSRI) |
| Target | Serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry / Neurology |
| Phase | FDA-approved |
Mechanism of action
Sertraline is a selective serotonin reuptake inhibitor (SSRI) that blocks the serotonin transporter protein, preventing the reabsorption of serotonin from the synaptic cleft back into presynaptic neurons. This increases serotonin concentration in the synapse, enhancing neurotransmission and improving mood regulation. The mechanism is thought to underlie its efficacy in treating depression, anxiety disorders, and related conditions.
Approved indications
- Major depressive disorder
- Obsessive-compulsive disorder
- Panic disorder
- Post-traumatic stress disorder
- Social anxiety disorder
- Generalized anxiety disorder
- Premenstrual dysphoric disorder
Common side effects
- Sexual dysfunction
- Nausea
- Headache
- Diarrhea
- Insomnia
- Somnolence
- Tremor
- Dry mouth
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sertraline [Zoloft] CI brief — competitive landscape report
- Sertraline [Zoloft] updates RSS · CI watch RSS
- Johns Hopkins University portfolio CI